ReviewInternational journal of molecular sciences2021
Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 71 citations in OpenAlex.
- Semiquantitative [¹²³I]FP-CIT SPECT metrics combined with machine learning improve clinical differentiation of Parkinson's disease and atypical parkinsonian syndrome.European journal of nuclear medicine and molecular imaging · 2026Article
- Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Peripheral blood transcriptomic signature is associated with cognitive impairment and freezing of gait in Parkinson's disease: a data-driven approach.NPJ Parkinson's disease · 2026Article
- 7 Tesla MRI with Quantitative Susceptibility Mapping: qualitative grading and quantitative focal measurements of the substantia nigra as a potential biomarker for Parkinson's disease.Neuroradiology · 2026Article
- Neuromelanin-sensitive MRI for identifying dopamine transporter imaging abnormality risk in idiopathic rapid eye movement sleep behavior disorder.Brain imaging and behavior · 2026Article
- Neuroimaging of the monoaminergic system in Parkinson's disease: A narrative review.Neuroimage. Reports · 2026Review
- Magnetic resonance imaging in Parkinson's disease: from routine imaging to molecular biomarkers - an update for radiologists.Polish journal of radiology · 2026Review
- A neuroimmune-enriched multibiofluid proteomic index associated with cognitive-motor progression in early Parkinson's disease: a longitudinal PPMI cohort study.Frontiers in immunology · 2026Article
- Longitudinal insights from iron accumulation in motor system of prodromal and clinical Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Review
- Review
- Serum Myeloperoxidase Activity Is Associated with Hoehn-Yahr Staging and Striatal Dopamine-Transporter Binding in Parkinson's Disease.Movement disorders clinical practice · 2025Article
- Stable Dopamine-Signaling mRNA Co-Expression in the Substantia Nigra Is Deregulated in Pathological Conditions, but Not in Dopamine Transporter Knockout Rats.Biomolecules · 2025Article
- Polygenic Risk Score Combined with Transcranial Sonography Refines Parkinson's Disease Risk Prediction.Movement disorders clinical practice · 2025Article
- Immunomodulatory Mechanisms Underlying Neurological Manifestations in Long COVID: Implications for Immune-Mediated Neurodegeneration.International journal of molecular sciences · 2025Review
- PI3K/mTOR Signaling Pathway Dual Inhibition for the Management of Neuroinflammation: Novel Insights from In Vitro Models.Biomolecules · 2025Article
- Liver fibrosis associated with more severe motor deficits in early Parkinson's disease.Clinical neurology and neurosurgery · 2025Article
- The Utilization and Impact of Dopamine Transporter Imaging in Diagnosing Movement Disorders at a Tertiary Care Hospital in Greece.Biomedicines · 2025Article
- A quantum inspired machine learning approach for multimodal Parkinson's disease screening.Scientific reports · 2025Article
- Association of Hemispheric Asymmetry of Dopamine-Transporter Binding with Risk of Parkinsonian Depression.Movement disorders clinical practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major goal of current clinical research in Parkinson's disease (PD) is the validation and standardization of biomarkers enabling early diagnosis, predicting outcomes, understanding PD pathophysiology, and demonstrating target engagement in clinical trials. Molecular imaging with specific dopamine-related tracers offers a practical indirect imaging biomarker of PD, serving as a powerful tool to assess the status of presynaptic nigrostriatal terminals. In this review we provide an update on the dopamine transporter (DAT) imaging in PD and translate recent findings to potentially valuable clinical practice applications. The role of DAT imaging as diagnostic, preclinical and predictive biomarker is discussed, especially in view of recent evidence questioning the incontrovertible correlation between striatal DAT binding and nigral cell or axon counts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.